152 related articles for article (PubMed ID: 31648115)
1. High drug efflux pump capacity and low DNA damage response induce doxorubicin resistance in canine hemangiosarcoma cell lines.
Morita A; Aoshima K; Gulay KCM; Onishi S; Shibata Y; Yasui H; Kobayashi A; Kimura T
Res Vet Sci; 2019 Dec; 127():1-10. PubMed ID: 31648115
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-214 Promotes Apoptosis in Canine Hemangiosarcoma by Targeting the COP1-p53 Axis.
Heishima K; Mori T; Sakai H; Sugito N; Murakami M; Yamada N; Akao Y; Maruo K
PLoS One; 2015; 10(9):e0137361. PubMed ID: 26335793
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma.
Fukumoto S; Saida K; Sakai H; Ueno H; Iwano H; Uchide T
Life Sci; 2016 Aug; 159():55-60. PubMed ID: 26835989
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of doxorubicin and tetrathiomolybdate on canine hemangiosarcoma cells.
Sloan CQ; Rodriguez CO
Am J Vet Res; 2018 Feb; 79(2):219-225. PubMed ID: 29359968
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
Pyuen AA; Meuten T; Rose BJ; Thamm DH
PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
[TBL] [Abstract][Full Text] [Related]
8. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
[TBL] [Abstract][Full Text] [Related]
9.
Maeda M; Ochiai K; Michishita M; Morimatsu M; Sakai H; Kinoshita N; Sakaue M; Onozawa E; Azakami D; Yamamoto M; Ishioka K; Sadahira T; Watanabe M; Tanaka Y
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35234262
[TBL] [Abstract][Full Text] [Related]
10. Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line.
Chen W; Liu I; Tomiyasu H; Lee J; Cheng C; Liao AT; Liu B; Liu C; Lin C
Vet J; 2019 Dec; 254():105398. PubMed ID: 31836165
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.
Sorenmo KU; Baez JL; Clifford CA; Mauldin E; Overley B; Skorupski K; Bachman R; Samluk M; Shofer F
J Vet Intern Med; 2004; 18(2):209-13. PubMed ID: 15058772
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of anticancer effects and enhanced doxorubicin cytotoxicity of xanthine derivatives using canine hemangiosarcoma cell lines.
Motegi T; Katayama M; Uzuka Y; Okamura Y
Res Vet Sci; 2013 Oct; 95(2):600-5. PubMed ID: 23871419
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
Sorenmo K; Samluk M; Clifford C; Baez J; Barrett JS; Poppenga R; Overley B; Skorupski K; Oberthaler K; Van Winkle T; Seiler G; Shofer F
J Vet Intern Med; 2007; 21(6):1347-54. PubMed ID: 18196746
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor-related apoptosis-inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro.
Goto M; Owaki K; Hirata A; Yanai T; Sakai H
Vet Comp Oncol; 2019 Sep; 17(3):285-297. PubMed ID: 30767429
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
16. KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma.
Gulay KCM; Aoshima K; Shibata Y; Yasui H; Yan Q; Kobayashi A; Kimura T
J Genet Genomics; 2021 Jul; 48(7):618-630. PubMed ID: 34023294
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study.
Lucroy MD; Clauson RM; Suckow MA; El-Tayyeb F; Kalinauskas A
BMC Vet Res; 2020 Nov; 16(1):447. PubMed ID: 33208160
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
19. Tenovin-6 induces the SIRT-independent cell growth suppression and blocks autophagy flux in canine hemangiosarcoma cell lines.
Igase M; Fujiki N; Shibutani S; Sakai H; Noguchi S; Nemoto Y; Mizuno T
Exp Cell Res; 2020 Mar; 388(1):111810. PubMed ID: 31891684
[TBL] [Abstract][Full Text] [Related]
20. Chromatin run-on sequencing analysis finds that ECM remodeling plays an important role in canine hemangiosarcoma pathogenesis.
Mukai C; Choi E; Sams KL; Klampen EZ; Anguish L; Marks BA; Rice EJ; Wang Z; Choate LA; Chou SP; Kato Y; Miller AD; Danko CG; Coonrod SA
BMC Vet Res; 2020 Jun; 16(1):206. PubMed ID: 32571313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
